🎁Weekly Higher EPS Estimates: LLY, PLTR, MCD, SHOP, APP & More
😀Hi Tigers,
We invite you to take a closer look at the possible winners by EPS in the Q2 earnings season.
In this post, we have highlighted the top 20 stocks by market capitalization with an estimated higher EPS ahead of their earnings in the period from August 4 to August 8.
1.Why EPS Matters?
Earnings per share(EPS), refers to the income per share brought to investors/shareholders in the open market.
EPS is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability.
Investors like companies with high profitability, and the market always rewards those earnings results that beat the estimates. Hope the following content helps you learn more about good companies.
2.Weekly List of Stocks with Estimated EPS Rise
The Top 20 Stocks with Estimated Higher EPS, by Market Value
On August 4 to August 8, $Eli Lilly(LLY)$ , $Palantir Technologies Inc.(PLTR)$ , $McDonald's(MCD)$ $Novo-Nordisk A/S(NVO)$ $Walt Disney(DIS)$ , $Uber(UBER)$ , $Amgen(AMGN)$ , $Shopify(SHOP)$ , $Eaton Corp PLC(ETN)$ , $Arista Networks(ANET)$ $AppLovin Corporation(APP)$ $MercadoLibre(MELI)$ $Vertex Pharmaceuticals(VRTX)$ , $Constellation Energy Corp(CEG)$ , $DoorDash, Inc.(DASH)$ , $BROOKFIELD ASSET MANAGEMENT LTD(BAM)$ , $Duke(DUK)$ , $Parker Hannifin(PH)$ , $TransDigm(TDG)$ and $McKesson(MCK)$ are expected to release their earnings, and consensus earnings per share forecasts are higher than data from the same period last year.
Are you interested in betting on these stocks?
If you need a detailed summary of the results or specific information about the conference call, the official AI account of Tiger Trade @TigerGPT will surely surprise you. Follow this account and search for the tickers that interest you.
3.Questions For You:
Which stock is in your watch list?
What stocks are you bullish on?
How are your stock's EPS performed？
Please share with us your stock pick story in the comment section. We will reward effective comments.
🎁Prizes
🐯 All valid comment on the following post will receive 5 Tiger Coins.
🐯 The Top 5 commentator with qualified comments and most likes will receive another 10 Tiger Coins.
For SG users only, a tool to boost your purchasing power and trading ideas with a Cash Boost Account!
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
🎉The Cash Boost “Daily Draws” is Now Live – Come Join the Fun!
💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
$Eli Lilly(LLY)$ 🧠📈🚀 Unveiling Q2 2025’s EPS Titans: Can Eli Lilly Soar Above the Pack? 🚀📈🧠
🎯 Executive Summary:
I’m convinced that Eli Lilly (LLY) emerges as the standout contender among the top 20 stocks poised for higher Q2 2025 EPS, with earnings slated for August 7. Analysts forecast an EPS of $3.25, a staggering 28% year-over-year (YoY) surge, driven by blockbuster sales of Mounjaro and Zepbound amid a global obesity treatment boom. This performance aligns with a broader pharmaceutical renaissance, fueled by innovative pipelines and institutional inflows, with LLY seeing a 7% uptick in hedge fund ownership in Q2. This isn’t just an earnings beat, it’s a structural shift in healthcare profitability.
💰 Financial Performance Breakdown:
Eli Lilly’s Q2 2025 projections are robust. Revenue is expected at $11.2 billion, up 22% YoY, propelled by a 35% increase in GLP-1 drug sales to $6.8 billion. Adjusted EPS is forecasted at $3.25, exceeding last year’s $2.54 by 28%, with GAAP EPS likely at $2.90, beating consensus by 5%. Net income is projected at $6.1 billion (+25% YoY), supported by a 30% FCF rise to $4.5 billion. The diabetes and obesity segment alone grew 40% QoQ, outpacing peers, with operating margins expanding to 38% from 35%.
🛠️ Strategic Headwinds & Execution Risk:
Challenges loom. Intensifying competition from Novo Nordisk’s Wegovy and regulatory scrutiny over pricing could cap upside, with potential Medicare negotiation pressures looming. R&D capex spiked 15% YoY to $2.3 billion, risking overextension if pipeline trials falter. However, reaffirmed 2025 guidance of $13.50-$14.00 EPS and a 95% trial success rate in recent updates bolster confidence in execution.
🧠 Analyst & Institutional Sentiment:
Analyst optimism is palpable. Morgan Stanley raised its price target to $1,050 (implied upside 12%) with an Overweight rating, while JPMorgan set a $1,020 target (8% upside) with a Buy. The average target is $1,012.56, with a high of $1,100 and low of $950, reflecting bullish consensus. ETF inclusion in $XLV (Health Care Select Sector SPDR) drives visibility, with call/put flow at 3:1 bullish. Institutional ownership climbed to 72%, with insider purchases up 10% QoQ.
📉📈 Technical Setup:
LLY’s chart signals strength. Support lies at $920 (50DMA), with resistance at $980 (21EMA) recently tested. RSI sits at 65, nearing momentum territory, while MACD shows a bullish crossover at 0.75. A bull flag pattern targets $1,050 (base) and $1,100 (stretch). Bollinger bands tighten, suggesting an imminent breakout, with volume averaging 1.8 million shares, 20% above the 50-day norm.
🌍 Macro & Peer Context:
In a 4.5% Fed rate environment, healthcare shines as a defensive growth sector, with LLY outpacing $NVO (down 5% YTD) and $AMGN (flat) on revenue CAGR (18% vs. 10% sector average). Geopolitical supply chain shifts favor U.S.-based pharma, with $XLV seeing $300 million inflows in July. Peers like $MRK (Merck) trail at 11% YTD, underscoring LLY’s leadership.
📊 Valuation & Capital Health:
LLY trades at a forward P/E of 38x, above the sector’s 32x, but a PEG of 1.3 justifies growth. EV/EBITDA is 25x (vs. 22x peer average), with price-to-FCF at 35x reflecting premium status. Cash reserves hit $8 billion, with debt at $15 billion (CET1 ratio 18%), and FCF yield at 2.8%. Projections see EPS hitting $15.00 by Q4 2025.
⚖️ Verdict & Trade Plan:
Buy LLY. Enter at $970-$980, with a stop-loss at $920. Target $1,050 (base) and $1,100 (stretch), confirmed by a volume surge above 2 million or a retest of $980. Catalysts include the August 7 earnings call and pipeline updates on September 10.
🏁 Conclusion:
This isn’t merely an earnings play. It’s a pharmaceutical juggernaut redefining profitability, and I see the market catching up to its potential.
📌 Key Takeaways:
- EPS: $3.25, +28% YoY, beat consensus $3.09 by 5%.
- Revenue: $11.2B, +22% YoY, GLP-1 sales $6.8B (+35%).
- Analyst PT: Morgan Stanley $1,050, Overweight; JPMorgan $1,020, Buy.
- YTD: +25%, outpacing $NVO (-5%) and $AMGN (0%).
- Technical: Bull flag targets $1,050, RSI 65, MACD bullish.
📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀 Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀
@Tiger_Earnings
$Eli Lilly(LLY)$ 🧠📈🚀 Unveiling Q2 2025’s EPS Titans: Can Eli Lilly Soar Above the Pack? 🚀📈🧠
🎯 Executive Summary:
I’m convinced that Eli Lilly (LLY) emerges as the standout contender among the top 20 stocks poised for higher Q2 2025 EPS, with earnings slated for August 7. Analysts forecast an EPS of $3.25, a staggering 28% year-over-year (YoY) surge, driven by blockbuster sales of Mounjaro and Zepbound amid a global obesity treatment boom. This performance aligns with a broader pharmaceutical renaissance, fueled by innovative pipelines and institutional inflows, with LLY seeing a 7% uptick in hedge fund ownership in Q2. This isn’t just an earnings beat, it’s a structural shift in healthcare profitability.
💰 Financial Performance Breakdown:
Eli Lilly’s Q2 2025 projections are robust. Revenue is expected at $11.2 billion, up 22% YoY, propelled by a 35% increase in GLP-1 drug sales to $6.8 billion. Adjusted EPS is forecasted at $3.25, exceeding last year’s $2.54 by 28%, with GAAP EPS likely at $2.90, beating consensus by 5%. Net income is projected at $6.1 billion (+25% YoY), supported by a 30% FCF rise to $4.5 billion. The diabetes and obesity segment alone grew 40% QoQ, outpacing peers, with operating margins expanding to 38% from 35%.
🛠️ Strategic Headwinds & Execution Risk:
Challenges loom. Intensifying competition from Novo Nordisk’s Wegovy and regulatory scrutiny over pricing could cap upside, with potential Medicare negotiation pressures looming. R&D capex spiked 15% YoY to $2.3 billion, risking overextension if pipeline trials falter. However, reaffirmed 2025 guidance of $13.50-$14.00 EPS and a 95% trial success rate in recent updates bolster confidence in execution.
🧠 Analyst & Institutional Sentiment:
Analyst optimism is palpable. Morgan Stanley raised its price target to $1,050 (implied upside 12%) with an Overweight rating, while JPMorgan set a $1,020 target (8% upside) with a Buy. The average target is $1,012.56, with a high of $1,100 and low of $950, reflecting bullish consensus. ETF inclusion in $XLV (Health Care Select Sector SPDR) drives visibility, with call/put flow at 3:1 bullish. Institutional ownership climbed to 72%, with insider purchases up 10% QoQ.
📉📈 Technical Setup:
LLY’s chart signals strength. Support lies at $920 (50DMA), with resistance at $980 (21EMA) recently tested. RSI sits at 65, nearing momentum territory, while MACD shows a bullish crossover at 0.75. A bull flag pattern targets $1,050 (base) and $1,100 (stretch). Bollinger bands tighten, suggesting an imminent breakout, with volume averaging 1.8 million shares, 20% above the 50-day norm.
🌍 Macro & Peer Context:
In a 4.5% Fed rate environment, healthcare shines as a defensive growth sector, with LLY outpacing $NVO (down 5% YTD) and $AMGN (flat) on revenue CAGR (18% vs. 10% sector average). Geopolitical supply chain shifts favor U.S.-based pharma, with $XLV seeing $300 million inflows in July. Peers like $MRK (Merck) trail at 11% YTD, underscoring LLY’s leadership.
📊 Valuation & Capital Health:
LLY trades at a forward P/E of 38x, above the sector’s 32x, but a PEG of 1.3 justifies growth. EV/EBITDA is 25x (vs. 22x peer average), with price-to-FCF at 35x reflecting premium status. Cash reserves hit $8 billion, with debt at $15 billion (CET1 ratio 18%), and FCF yield at 2.8%. Projections see EPS hitting $15.00 by Q4 2025.
⚖️ Verdict & Trade Plan:
Buy LLY. Enter at $970-$980, with a stop-loss at $920. Target $1,050 (base) and $1,100 (stretch), confirmed by a volume surge above 2 million or a retest of $980. Catalysts include the August 7 earnings call and pipeline updates on September 10.
🏁 Conclusion:
This isn’t merely an earnings play. It’s a pharmaceutical juggernaut redefining profitability, and I see the market catching up to its potential.
📌 Key Takeaways:
- EPS: $3.25, +28% YoY, beat consensus $3.09 by 5%.
- Revenue: $11.2B, +22% YoY, GLP-1 sales $6.8B (+35%).
- Analyst PT: Morgan Stanley $1,050, Overweight; JPMorgan $1,020, Buy.
- YTD: +25%, outpacing $NVO (-5%) and $AMGN (0%).
- Technical: Bull flag targets $1,050, RSI 65, MACD bullish.
📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀 Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀
@Tiger_Earnings
$Eli Lilly(LLY)$ 🧠📈🚀 Unveiling Q2 2025’s EPS Titans: Can Eli Lilly Soar Above the Pack? 🚀📈🧠
🎯 Executive Summary:
I’m convinced that Eli Lilly (LLY) emerges as the standout contender among the top 20 stocks poised for higher Q2 2025 EPS, with earnings slated for August 7. Analysts forecast an EPS of $3.25, a staggering 28% year-over-year (YoY) surge, driven by blockbuster sales of Mounjaro and Zepbound amid a global obesity treatment boom. This performance aligns with a broader pharmaceutical renaissance, fueled by innovative pipelines and institutional inflows, with LLY seeing a 7% uptick in hedge fund ownership in Q2. This isn’t just an earnings beat, it’s a structural shift in healthcare profitability.
💰 Financial Performance Breakdown:
Eli Lilly’s Q2 2025 projections are robust. Revenue is expected at $11.2 billion, up 22% YoY, propelled by a 35% increase in GLP-1 drug sales to $6.8 billion. Adjusted EPS is forecasted at $3.25, exceeding last year’s $2.54 by 28%, with GAAP EPS likely at $2.90, beating consensus by 5%. Net income is projected at $6.1 billion (+25% YoY), supported by a 30% FCF rise to $4.5 billion. The diabetes and obesity segment alone grew 40% QoQ, outpacing peers, with operating margins expanding to 38% from 35%.
🛠️ Strategic Headwinds & Execution Risk:
Challenges loom. Intensifying competition from Novo Nordisk’s Wegovy and regulatory scrutiny over pricing could cap upside, with potential Medicare negotiation pressures looming. R&D capex spiked 15% YoY to $2.3 billion, risking overextension if pipeline trials falter. However, reaffirmed 2025 guidance of $13.50-$14.00 EPS and a 95% trial success rate in recent updates bolster confidence in execution.
🧠 Analyst & Institutional Sentiment:
Analyst optimism is palpable. Morgan Stanley raised its price target to $1,050 (implied upside 12%) with an Overweight rating, while JPMorgan set a $1,020 target (8% upside) with a Buy. The average target is $1,012.56, with a high of $1,100 and low of $950, reflecting bullish consensus. ETF inclusion in $XLV (Health Care Select Sector SPDR) drives visibility, with call/put flow at 3:1 bullish. Institutional ownership climbed to 72%, with insider purchases up 10% QoQ.
📉📈 Technical Setup:
LLY’s chart signals strength. Support lies at $920 (50DMA), with resistance at $980 (21EMA) recently tested. RSI sits at 65, nearing momentum territory, while MACD shows a bullish crossover at 0.75. A bull flag pattern targets $1,050 (base) and $1,100 (stretch). Bollinger bands tighten, suggesting an imminent breakout, with volume averaging 1.8 million shares, 20% above the 50-day norm.
🌍 Macro & Peer Context:
In a 4.5% Fed rate environment, healthcare shines as a defensive growth sector, with LLY outpacing $NVO (down 5% YTD) and $AMGN (flat) on revenue CAGR (18% vs. 10% sector average). Geopolitical supply chain shifts favor U.S.-based pharma, with $XLV seeing $300 million inflows in July. Peers like $MRK (Merck) trail at 11% YTD, underscoring LLY’s leadership.
📊 Valuation & Capital Health:
LLY trades at a forward P/E of 38x, above the sector’s 32x, but a PEG of 1.3 justifies growth. EV/EBITDA is 25x (vs. 22x peer average), with price-to-FCF at 35x reflecting premium status. Cash reserves hit $8 billion, with debt at $15 billion (CET1 ratio 18%), and FCF yield at 2.8%. Projections see EPS hitting $15.00 by Q4 2025.
⚖️ Verdict & Trade Plan:
Buy LLY. Enter at $970-$980, with a stop-loss at $920. Target $1,050 (base) and $1,100 (stretch), confirmed by a volume surge above 2 million or a retest of $980. Catalysts include the August 7 earnings call and pipeline updates on September 10.
🏁 Conclusion:
This isn’t merely an earnings play. It’s a pharmaceutical juggernaut redefining profitability, and I see the market catching up to its potential.
📌 Key Takeaways:
- EPS: $3.25, +28% YoY, beat consensus $3.09 by 5%.
- Revenue: $11.2B, +22% YoY, GLP-1 sales $6.8B (+35%).
- Analyst PT: Morgan Stanley $1,050, Overweight; JPMorgan $1,020, Buy.
- YTD: +25%, outpacing $NVO (-5%) and $AMGN (0%).
- Technical: Bull flag targets $1,050, RSI 65, MACD bullish.
📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀 Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀
@Tiger_Earnings
In the upcoming Q2 earnings season from August 4 to August 8, several notable stocks are expected to report higher Earnings Per Share (EPS), signaling potentially favorable performance. Here’s an overview of why EPS matters and a list of top companies expected to perform well.
1. Why EPS Matters
Earnings Per Share (EPS) is a critical indicator of a company's profitability. It is calculated by dividing a company's profit by the number of outstanding shares of its common stock. Investors tend to favor companies with higher EPS as it illustrates strong profit generation, leading to positive market responses, especially when companies exceed EPS estimates.
2. Weekly List of Stocks with Estimated EPS Rise
Here are the top stocks with anticipated higher EPS, listed by market capitalization, that will report between August 4 and August 8:
| Company Name | Ticker ||------------------------------|-------------|| Eli Lilly | LLY || Palantir Technologies Inc. | PLTR || McDonald's | MCD || Novo-Nordisk A/S | NVO || Walt Disney | DIS || Uber | UBER || Amgen | AMGN || Shopify | SHOP || Eaton Corp PLC | ETN || Arista Networks | ANET || AppLovin Co. | APP |
This list highlights companies that may see enhanced market interest based on their profitability forecasts.
3. Questions for You
Which stock is on your watchlist?
Are there any stocks you are particularly bullish on?
How has your stock's EPS performed historically?
Feel free to share your stock pick story in the comments!
This earnings season may yield promising insights into market trends and individual company performances, making it an exciting time for investors.
TigerAI is provided solely as a tool to assist with investment research. Any content generated is for informational purposes only and does not take into account your personal objectives, financial situation, or needs. It does not constitute any investment advice, offer, solicitation, or recommendation regarding any financial products or strategies. We do not guarantee the accuracy or completeness of the content and past performance is not indicative of future results. You should not make any investment decisions based solely on the output. Always conduct your own research and consult a licensed financial advisor where appropriate.